TG Therapeutics Inc (TGTX) Stock Analysis

Verdict: HOLD

BRIUMVI's robust 81% revenue growth is currently overshadowed by chronic EPS misses and aggressive spending that depletes the cash cushion.

Investment score: 62/100

Analysis as of

Is TG Therapeutics Inc stock worth reviewing? AI model thesis

TGTX is a high-growth biotech with a commercial success in BRIUMVI but a credibility gap in earnings execution. The model views the recent 17% sell-off as an overreaction to an EPS miss that was paired with a revenue beat and guidance raise.

7-factor investment score

TG Therapeutics Inc opportunities and risks

What speaks for TGTX

What speaks against TGTX

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
TGTX15.2x8.8x55.0x82.4%55.2%-0.2%
IMVTn/a0.0xn/a0.0%0.0%-5.2%
PCVXn/a0.0xn/a0.0%0.0%-10.0%
IBRXn/a45.2xn/a94.6%-598.6%-1.9%
RYTMn/a29.4xn/a89.0%-86.0%-1.7%
COGTn/a0.0xn/a0.0%0.0%-4.3%
Peer mediann/a0.0xn/a0.0%0.0%-4.3%

Frequently asked questions about TG Therapeutics Inc (TGTX)

Is TGTX stock a good investment?

The cached TradeMates AI model rates TG Therapeutics Inc as HOLD with an investment score of 62/100. TGTX is a high-growth biotech with a commercial success in BRIUMVI but a credibility gap in earnings execution. The model views the recent 17% sell-off as an overreaction to an EPS miss that was paired with a revenue beat and guidance raise. This is algorithmic model output, not personal investment advice.

Is TGTX stock a buy?

The TradeMates model verdict for TGTX is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.